PTC Therapeutics PTCT Business Segments — Interest Expense Nonoperating

Similar metrics at other companies

SEN

SENEALifo Impact — Interest Expense Nonoperating

$0—

CWCOServices — Interest Expense Nonoperating

$2.74K+79.1%

BRORetail — Interest Expense Nonoperating

$5M-66.7%

ELACommercial — Interest Expense Nonoperating

$40.39K-22.7%

ELAConsumer — Interest Expense Nonoperating

$38.39K-29.0%

SPAIOther — Interest Expense Nonoperating

$1.34K-1.1%

FAQ

What is PTC Therapeutics's business segments — interest expense nonoperating?

PTC Therapeutics (PTCT) reported business segments — interest expense nonoperating of $67.02M in Q1 2026.

How has PTC Therapeutics's business segments — interest expense nonoperating changed year-over-year?

PTC Therapeutics's business segments — interest expense nonoperating increased by 30.5% year-over-year, from $51.34M to $67.02M.

What is the long-term trend for PTC Therapeutics's business segments — interest expense nonoperating?

Over 2 years (2023 to 2025), PTC Therapeutics's business segments — interest expense nonoperating has grown at a 26.0% compound annual growth rate (CAGR), from $142.51M to $226.31M.

What does business segments — interest expense nonoperating mean?

This metric represents the costs incurred by the Life Science segment related to debt obligations and financing activities that are not part of core operating expenses. It reflects the financial burden of the segment's capital structure and debt servicing requirements. Monitoring this helps investors assess the segment's financial leverage and the impact of interest-bearing liabilities on its overall profitability.